Skip to main content
Fig. 7 | BMC Complementary Medicine and Therapies

Fig. 7

From: Anti-atherosclerotic effects of naringenin and quercetin from Folium Artemisiae argyi by attenuating Interleukin-1 beta (IL-1β)/ matrix metalloproteinase 9 (MMP9): network pharmacology-based analysis and validation

Fig. 7

The qRT-PCR results, mRNA expression of IL6, IL-1β and MMP9 in macrophage (RAW264.7 stimulated with LPS) treated with quercetin and naringenin. The anti-inflammation effect of quercetin and naringenin indicated MMP9 might be the potential target. LPS: lipopolysaccharide. * P < 0.05,** P < 0.01,*** P < 0.001, **** P < 0.0001. (A) Control-IL-6 vs. Treated-LPS P < 0.0001,Treated-LPS vs. LPS+10 μM quercetin P < 0.0001, LPS+10 μM quercetin vs. LPS+20 μM quercetin P < 0.0001, LPS+20 μM quercetin vs. LPS+50 μM quercetin P = 0.0006 (B) Control-IL-1β vs. Treated-LPS P < 0.0001, Treated-LPS vs. LPS+10 μM naringenin P < 0.0001, LPS+10 μM naringenin vs. LPS+20 μM naringenin P < 0.0001, LPS+20 μM naringenin vs. LPS+50 μM naringenin P = 0.1643 (C) Control-MMP9 vs. Treated-LPS P < 0.0001, Treated-LPS vs. LPS+10 μM quercetin P = 0.0076, LPS+10 μM quercetin vs. LPS+50 μM quercetin P = 0.0266 (D) Control-MMP9 vs. Treated-LPS P = 0.0007, Treated-LPS vs. LPS+20 μM naringenin P = 0.0035, Treated-LPS vs. LPS+50 μM naringenin P = 0.0017

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us